CapForce Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CapForce Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.20M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | $3.42M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $2.61M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $4.31M | Mar 30, 2023 |
| FY2017 | Dec 31, 2017 | $3.21M | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $4.03M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $3.16M | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $4.13M | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $4.31M | Mar 30, 2022 |
| FY2021 | Dec 31, 2020 | $4.21M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.50M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.95M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $3.21M | Feb 27, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $11.99M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | ($32.67M) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | ($37.28M) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | ($34.81M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($26.21M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($12.45M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($13.37M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($15.42M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($19.17M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($17.35M) | Mar 24, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $324.7K | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | ($30.75M) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | ($34.57M) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | ($23.27M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($22.72M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($12.27M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($13.18M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($15.27M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($19.01M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($15.06M) | Mar 24, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $48.8K | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | $4.73M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $8.17M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $10.91M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.96M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $5.12M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $5.68M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $6.88M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $8.61M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $6.00M | Mar 24, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($4.87M) | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | ($14.32M) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | ($20.45M) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | ($21.48M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($23.40M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($11.51M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($11.07M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($14.30M) | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $800.4K | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $590.8K | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $1.98M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $130.4K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $31.8K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $147.8K | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $277.0K | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $123.5K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $185.3K | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $39.5K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.86M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.88M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $25.81M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $71.67M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $49.75M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $10.42M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $8.95M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $6.62M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $8.98M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $13.76M | Mar 24, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.48M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | $13.44M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $18.24M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $30.45M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $28.56M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.13M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $5.64M | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $5.22M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $5.82M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $6.27M | Mar 24, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.38M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | ($11.56M) | Aug 21, 2025 |
| FY2024 | Dec 31, 2022 | $7.58M | Aug 21, 2025 |
| FY2023 | Dec 31, 2021 | $41.22M | Jun 3, 2024 |
| FY2022 | Dec 31, 2020 | $21.19M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $4.29M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $3.31M | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | $1.40M | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $3.17M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $7.49M | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $0 | Jun 3, 2024 |
| FY2023 | Dec 31, 2021 | $7.45M | Jun 3, 2024 |
| FY2022 | Dec 31, 2020 | $8.02M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $600.8K | Mar 30, 2022 |
| FY2019 | Dec 31, 2018 | $600.8K | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | $600.8K | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $600.8K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $637.5K | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $0 | Mar 30, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($293.50M) | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | ($305.49M) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | ($272.82M) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | ($235.54M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($200.74M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($174.52M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($162.08M) | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | ($148.71M) | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | ($133.29M) | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | ($114.12M) | Mar 24, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.31M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | $1.15M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | $7.44M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $36.08M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.36M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.71M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $4.57M | Mar 24, 2020 |
| FY2019 | Dec 31, 2017 | $1.85M | Mar 24, 2020 |
| FY2018 | Dec 31, 2016 | $4.12M | Feb 27, 2019 |
| FY2017 | Dec 31, 2015 | $7.81M | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $4.85M | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | $7.18M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.38M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $329.5K | Mar 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2 | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | (41) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | (152) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | (22) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 2 | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | (41) | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | (152) | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | (22) | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 10.07M | Aug 21, 2025 |
| FY2024 | Dec 31, 2023 | 1.28M | Aug 21, 2025 |
| FY2023 | Dec 31, 2022 | 289,992 | Jun 3, 2024 |
| FY2022 | Dec 31, 2021 | 2.32M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 25.09M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 5.58M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 432,286 | Mar 24, 2020 |
| FY2018 | Dec 31, 2017 | 2.27M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 1.01M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 12.55M | Mar 24, 2017 |